1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fibrosis - Pipeline Review, H1 2015

Fibrosis - Pipeline Review, H1 2015

  • May 2015
  • -
  • Global Markets Direct
  • -
  • 151 pages

Fibrosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Fibrosis - Pipeline Review, H1 2015’, provides an overview of the Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Fibrosis - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fibrosis Overview 8
Therapeutics Development 9
Pipeline Products for Fibrosis - Overview 9
Pipeline Products for Fibrosis - Comparative Analysis 10
Fibrosis - Therapeutics under Development by Companies 11
Fibrosis - Therapeutics under Investigation by Universities/Institutes 15
Fibrosis - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Fibrosis - Products under Development by Companies 19
Fibrosis - Products under Investigation by Universities/Institutes 22
Fibrosis - Companies Involved in Therapeutics Development 23
Acceleron Pharma, Inc. 23
AiCuris GmbH and Co. KG 24
AnaMar AB 25
Arena Pharmaceuticals, Inc. 26
Bristol-Myers Squibb Company 27
Digna Biotech, S.L. 28
F. Hoffmann-La Roche Ltd. 29
FibroGen, Inc. 30
Five Prime Therapeutics, Inc. 31
Galectin Therapeutics, Inc. 32
GenKyoTex S.A. 33
GlycoMimetics, Inc. 34
HanAll Biopharma Co., Ltd. 35
Intercept Pharmaceuticals, Inc. 36
Isarna Therapeutics GmbH 37
KineMed, Inc. 38
Lycera Corp. 39
MandalMed, Inc. 40
miRagen Therapeutics, Inc. 41
Neumedicines Inc. 42
Pfizer Inc. 43
Promedior, Inc. 44
ProMetic Life Sciences Inc. 45
RuiYi Inc. 46
Scholar Rock, Inc. 47
Siena Biotech S.p.A. 48
SK Chemicals Co., Ltd. 49
Taisho Pharmaceutical Co., Ltd. 50
TRACON Pharmaceuticals, Inc. 51
UCB S.A. 52
Vericel Corporation 53
VivaCell Biotechnology Espana S.L. 54
Fibrosis - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Target 56
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
AIC-649 - Drug Profile 64
AMAP-102 - Drug Profile 65
Antibodies for Fibrosis - Drug Profile 67
Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile 68
APD-371 - Drug Profile 69
ASPH-0047 - Drug Profile 70
ASPH-1047 - Drug Profile 72
Biologics to Inhibit TGF-beta 1 for Fibrosis - Drug Profile 74
disitertide - Drug Profile 75
Drug to Modulate Galectin for Fibrosis, Inflammation and Cancer - Drug Profile 77
G-XXX - Drug Profile 78
Galectin-3C - Drug Profile 79
GC-4419 - Drug Profile 81
GKT-136901 - Drug Profile 82
HL-156FIB - Drug Profile 84
INT-767 - Drug Profile 85
ixmyelocel-T - Drug Profile 87
KBP-7018 - Drug Profile 90
MGN-4220 - Drug Profile 91
NCE-401 - Drug Profile 92
NMIL-121 - Drug Profile 93
noscapine - Drug Profile 95
NPH-09 - Drug Profile 96
P-006 - Drug Profile 97
PBI-4419 - Drug Profile 98
PF-06473871 - Drug Profile 99
Polysaccharides to Inhibit Galectin for Fibrosis, Inflammation and Cancer - Drug Profile 101
PRI-724 - Drug Profile 102
PRM-151 - Drug Profile 104
Protein for Fibrosis - Drug Profile 106
Proteins for Fibrosis - Drug Profile 107
Recombinant Protein to Inhibit BMP-1 like Proteinases for Fibrotic Disorders - Drug Profile 108
RYI-018 - Drug Profile 109
Small molecule for cancer and fibrotic disease - Drug Profile 110
Small Molecule for Fibrotic Diseases - Drug Profile 111
Small Molecule to Antagonize 5-HT2 Receptor for Cardiovascular, Inflammation, Inflammatory Pain and Fibrosis - Drug Profile 112
Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases - Drug Profile 113
Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis - Drug Profile 114
Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease - Drug Profile 115
Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile 116
Small Molecule to Inhibit Rho Kinase for Fibrosis - Drug Profile 117
Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology - Drug Profile 118
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 119
Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis - Drug Profile 120
Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis - Drug Profile 121
Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile 122
Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 123
SphK2 Program - Drug Profile 124
TRC-205 - Drug Profile 125
Trophokine - Drug Profile 126
VCE-0048 - Drug Profile 127
Fibrosis - Recent Pipeline Updates 128
Fibrosis - Dormant Projects 142
Fibrosis - Discontinued Products 145
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 146
Disclaimer 147

List of Tables
Number of Products under Development for Fibrosis, H1 2015 13
Number of Products under Development for Fibrosis - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Comparative Analysis by Unknown Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Fibrosis - Pipeline by Acceleron Pharma, Inc., H1 2015 27
Fibrosis - Pipeline by AiCuris GmbH and Co. KG, H1 2015 28
Fibrosis - Pipeline by AnaMar AB, H1 2015 29
Fibrosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 30
Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 31
Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015 32
Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 33
Fibrosis - Pipeline by FibroGen, Inc., H1 2015 34
Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H1 2015 35
Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015 36
Fibrosis - Pipeline by GenKyoTex S.A., H1 2015 37
Fibrosis - Pipeline by GlycoMimetics, Inc., H1 2015 38
Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 39
Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 40
Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2015 41
Fibrosis - Pipeline by KineMed, Inc., H1 2015 42
Fibrosis - Pipeline by Lycera Corp., H1 2015 43
Fibrosis - Pipeline by MandalMed, Inc., H1 2015 44
Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2015 45
Fibrosis - Pipeline by Neumedicines Inc., H1 2015 46
Fibrosis - Pipeline by Pfizer Inc., H1 2015 47
Fibrosis - Pipeline by Promedior, Inc., H1 2015 48
Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015 49
Fibrosis - Pipeline by RuiYi Inc., H1 2015 50
Fibrosis - Pipeline by Scholar Rock, Inc., H1 2015 51
Fibrosis - Pipeline by Siena Biotech S.p.A., H1 2015 52
Fibrosis - Pipeline by SK Chemicals Co., Ltd., H1 2015 53
Fibrosis - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 54
Fibrosis - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 55
Fibrosis - Pipeline by UCB S.A., H1 2015 56
Fibrosis - Pipeline by Vericel Corporation, H1 2015 57
Fibrosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 58
Assessment by Monotherapy Products, H1 2015 59
Number of Products by Stage and Target, H1 2015 61
Number of Products by Stage and Mechanism of Action, H1 2015 63
Number of Products by Stage and Route of Administration, H1 2015 65
Number of Products by Stage and Molecule Type, H1 2015 67
Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015 132
Fibrosis - Dormant Projects, H1 2015 146
Fibrosis - Dormant Projects (Contd..1), H1 2015 147
Fibrosis - Dormant Projects (Contd..2), H1 2015 148
Fibrosis - Discontinued Products, H1 2015 149

List of Figures
Number of Products under Development for Fibrosis, H1 2015 13
Number of Products under Development for Fibrosis - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 15
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Products, H1 2015 21
Assessment by Monotherapy Products, H1 2015 59
Number of Products by Top 10 Targets, H1 2015 60
Number of Products by Stage and Top 10 Targets, H1 2015 60
Number of Products by Top 10 Mechanism of Actions, H1 2015 62
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 62
Number of Products by Top 10 Routes of Administration, H1 2015 64
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 65
Number of Products by Top 10 Molecule Types, H1 2015 66
Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.